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ABSTRACT
DISSOCIATION OF β1 AND β2 ADRENERGIC RECEPTOR
SUBTYPES IN RETRIEVAL AND RECONSOLIDATION OF A
COCAINE CONDITIONED PLACE PREFERENCE
by

Michael K. Fitzgerald

The University of Wisconsin - Milwaukee, 2013
Under the Supervision of Devin Mueller

Drug-seeking behavior is maintained by encounters with drug-associated cues, and
disrupting retrieval or reconsolidation of the drug-cue associations could reduce
the risk of relapse. Previous work has shown β-adrenergic receptor (β-AR)
antagonists can prevent retrieval or reconsolidation of a cocaine conditioned place
preference (CPP) when administered either before or after test, respectively (Otis
and Mueller, 2011; Otis et al., 2013). However, the specific β-AR subtypes that
mediate retrieval and reconsolidation of a cocaine CPP remain unknown. Here we
used selective blockade of β1 or β2-AR subtypes to determine the effects on
retrieval and reconsolidation of a cocaine CPP. During conditioning, rats were
trained to associate one chamber, but not another, with cocaine. Memory retrieval
was then tested by allowing the rats access to both chambers, resulting in a CPP
for the previously cocaine-paired side. Pre-test injection of the β1-AR antagonist
betaxolol at 20 mg/kg, i.p. but not 3 mg/kg prevented expression of a cocaineinduced CPP, indicating β1-AR involvement in memory retrieval. During
subsequent drug-free tests, saline-treated rats continued to show a CPP, whereas
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betaxolol-treated rats did not. Moreover, treatment with the higher dose of
betaxolol prevented subsequent reinstatement to a priming injection of cocaine.
Unlike betaxolol administration, pre-test injection of the β2-AR antagonist ICI
118,551 (4 or 8 mg/kg, i.p.) had no affect on expression of a cocaine-induced CPP.
On subsequent tests, however, vehicle- and 4 mg/kg ICI 118,551-treated rats
continued to show a CPP whereas 8 mg/kg ICI 118,551-treated rats did not,
indicative of a deficit in reconsolidation following this higher dose. Moreover, ICI
118,551 treatment prevented subsequent reinstatement to a priming injection of
cocaine. Thus, we conclude that retrieval of a CPP is dependent on β1-ARs
whereas reconsolidation of a CPP is dependent on β2-ARs. Finally, co-injection of
betaxolol (20 mg/kg) and ICI 118,551 (8 mg/kg) prevented CPP expression on that
and subsequent CPP tests, resulting in a long-lasting retrieval deficit that prevented
reinstatement to a priming injection of cocaine. Our findings support the use of βAR antagonists as adjuncts for addiction therapies by preventing retrieval and
reconsolidation of drug-associated memories and providing protection against
relapse.
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Introduction
Drug-associated cues
Addiction is characterized as a compulsively relapsing pattern of drug use that
persists in the face of negative consequences and a desire to stop using. Despite the will
to end drug use, drug-seeking behavior can be maintained by encounters with drugassociated cues. Addicts respond to cues such as the drugs themselves, drug
paraphernalia, people using drugs, and environments where drugs were used (O’Brien et
al., 1977; Ehrman et al., 1992; Foltin and Haney, 2000). Research indicates that cues
become associated with the drug in stages, including acquisition and consolidation
(Duarte et al., 2003). Following associative memory acquisition and consolidation,
retrieval can be triggered by the cue resulting in behavioral expression (drug seeking) and
subsequent reconsolidation of the associative memory (Sara, 2000). Preventing retrieval
or reconsolidation of drug-associated memories provoked by cues could therefore limit
relapse susceptibility. Previously, our lab has shown that retrieval of cocaine-associated
memories is mediated by the activation of β-adrenergic receptors using the conditioned
place preference (CPP) procedure (Otis & Mueller, 2011). The CPP procedure is a useful
animal model of drug seeking because it connects the environmental stimuli with drug
administration. To disrupt cocaine-associated memory retrieval, Otis and Mueller (2011)
administered propranolol, a non-specific β-adrenergic receptor (β-AR) blocker which has
affinity for both β1 and β2 β-AR subtypes, immediately prior to a retrieval test (see
Figure 1). However, it remains unknown if one or both β-AR subtypes mediate this
retrieval blockade. Isolating the specific receptor subtype that prevents cue-induced
memory retrieval will lead to an understanding of the mechanisms underlying cocaine-
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associated memory retrieval and could provide insight into potential treatment options for
cocaine addiction.
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The conditioned place preference procedure
The mechanisms of drug-associated memory retrieval can be investigated using
the conditioned place preference (CPP) paradigm. This paradigm is an animal model of
drug seeking in which rats learn to associate environmental stimuli with cocaine. During
training, rats are given experimenter-delivered cocaine or saline followed by exposure to
one of two chambers. Following training, rats are given full access to both the cocaineand saline-paired chambers, along with a neutral center chamber. Rats spend more time
in the previously cocaine-paired chamber during this trial, thus expressing a cocaineinduced CPP. When a CPP is expressed, investigators can be certain that the rats
acquired, consolidated, and retrieved this cocaine-associated memory. Additionally, rats
that express a CPP on additional test trials demonstrate that they were able reconsolidate
the cocaine-associated memory from the previous trial.

Memory retrieval and the noradrenergic system
Studies have demonstrated that memory expression can be enhanced by pre-test
treatment of nicotine (Faiman et al., 1992), cocaine, (Rodriguez et al., 1993), or
amphetamine (Sara & Deweer, 1982). These drugs are nonspecific, but all of them
enhance noradrenergic signaling. In addition, stimulation of the noradrenergic system
influences memory task performance. For example, blockade of α 2-adrenergic
autoreceptors, which normally prevent norepinephrine from being released, leads to an
increase in rat performance in maze navigation after the task had been forgotten (Sara,
1985; Sara & Devauges, 1989). Moreover, stimulation of the locus coeruleus (LC), a
major nucleus of noradrenergic cell bodies (Dahlstroem & Fuxe, 1964), also enhances
memory expression after forgetting. This enhancement is prevented by the noradrenergic
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β-AR antagonist propranolol (Devauges & Sara, 1991). Taken together, these studies
demonstrate that memory retrieval can be enhanced by stimulation of the noradrenergic
system, and that this effect is also dependent on β-AR signaling.
Although retrieval of cue-associated memories is enhanced by activating neurons
in the LC (Sara, 2009; Sterpenich et al., 2006) to release norepinephrine (Cassens et al.,
1980; Feenstra et al, 2001; Mingote et al., 2004), the necessity of norepinephrine for
retrieval has only recently been explored. Seminal work by Murchison and colleagues
(2004) showed that mice that lack the enzyme for the synthesis of norepinephrine
(dopamine β-hydroxylase (DBH)) were able to acquire a contextual fear memory, but
were unable to express this memory on subsequent daily trials for seven days. Similar
results were found using the Morris water maze, a task requiring spatial memory.
Moreover, normal rats that were administered β-AR antagonists showed impaired
contextual fear expression while β-AR agonists enhanced expression. Interestingly, DBH
knockout mice were able to perform as well as controls on several tasks involving distinct
cues rather than contexts. From these data, the authors concluded that β-AR signaling is
necessary for the retrieval of contextual, but not cued memory tasks.
Although Murchinson and colleagues suggest a distinct role for β-ARs in retrieval
of contextual, but not cued memories, there is evidence that β-ARs are necessary for cueassociated memories as well. Rodriguez-Romaguera and colleagues (2009) showed that
β-AR blockade with propranolol attenuated cue-induced fear expression. Additionally, in
the CPP paradigm, it has been shown that propranolol blocks reinstatement of an
extinguished CPP in a distinguishably different context than drug-associated cue
conditioning (Mantsch et al., 2010). Human studies have shown that propranolol
administration can attenuate cued recall of heroin- or emotionally-related words (Kroes,
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Strange, & Dolan, 2010; Zhao et al., 2010). This evidence supports the necessity of βAR activation in retrieval of both context- and cue-associated memories.

Different structures, different roles in drug-related memory
Mechanisms of drug-associated memories can be investigated through
pharmacological manipulation at different time points throughout CPP experiments. Otis
and Mueller (2011) demonstrated that rats given an intraperitoneal (i.p.) injection of
propranolol prior to an initial CPP trial were unable to retrieve the CPP during the first
and subsequent daily CPP trials. Furthermore Otis, Dashew, and Mueller (2013)
identified that infusing nadolol, another non-specific beta-AR blocker, into the prelimbic
medial prefrontal cortex (PL-mPFC) prior to the rat’s first CPP trial also blocked retrieval
on the initial and subsequent daily trials.
While retrieval of a CPP occurs upon exposure to the apparatus, reconsolidation
of the retrieved memory is a process that occurs after the rats have been removed from
the apparatus. The introduction of pharmacological agents to rats after the CPP session
could then disrupt the reconsolidation of the cocaine-associated memory.
Reconsolidation disruption makes it difficult to retrieve a CPP memory from long-term
memory on subsequent trials. Fricks-Gleason and Marshall (2008) demonstrated that
daily post-retrieval systemic injections of propranolol decreased CPP by interfering with
reconsolidation of the memory for the association between the drug-paired side and the
reinforcing effects of the drug rather than facilitating new extinction learning. The locus
of action has since been deteremined. Otis et al., (2013) and Bernardi, Ryabinin, Berger,
and Lattal (2009) investigated the role of amygdala β–ARs in reconsolidation of a
cocaine CPP. After retrieval of a CPP, infusions of propranolol or nadolol into the
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basolateral amygdala (BLA) immediately post-trial resulted in a retrieval deficit on
subsequent daily trials. Thus reconsolidation had been disrupted by blockade of β–ARs
in the BLA.
To show that the PL-mPFC and BLA have distinctly different roles in retrieval
and reconsolidation, each structure was tested using the same pre- or post-trial timing of
infusions (Otis et al., 2013). The PL-mPFC was shown to mediate retrieval of a CPP, but
not reconsolidation. When propranolol or nadolol was infused into the PL-mPFC after
the first CPP trial, the rats continued to express a CPP on subsequent trials. Had
reconsolidation been jeopardized, the rats would not have been able to express a CPP on
subsequent CPP trials as observed with post-trial BLA infusions. The BLA, on the other
hand, is involved with reconsolidation and not retrieval as infusions with propranolol or
nadolol prior to the first CPP trial did not disrupt expression of a CPP. However, on
subsequent trials, these rats were unable to express a CPP demonstrating that
reconsolidation had been blocked (Otis et al., 2013).

Different β –AR subtypes, different effects on memory
Activation of β-ARs in the CNS activates adenylyl cyclase to increase the levels
of intracellular cAMP, which activates protein kinase A (PKA) (Mueller, Porter, &
Quirk, 2008). When PKA becomes activated, it can have local effects such as increasing
cell excitability, increasing NMDAr-mediated calcium current (Skeberdis et al., 2006),
and facilitating AMPA receptor trafficking (Snyder et al., 2005; Hu et al., 2007). In the
CNS, there are different β–AR sub-types. Two specifically, β1-AR and β2-AR, have
received increasing interest. Both β–AR subtypes stimulate adenylyl cyclase by coupling
to the guanine nucleotide protein which leads to the increase of intracelular cAMP and
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activation of PKA. Interestingly, equal doses of the non-selective β–AR agonist,
isoproterenol, stimulates β2-AR adenlyl cyclase approximately 50% more than β1-AR
even though both β–AR subtypes show equal affinity for isoproterenol (Green, Holt, &
Liggett, 1992). Although β2-AR leads to a stronger stimulation of adenlyl cyclase, β1AR has been found in much higher concentration than β2-AR within forebrain structures
such as the cerebral cortex, caudate, hippocampus and amygdala (Rainbow, Parsons, &
Wolfe, 1984).
The differences in signaling activity and subtype receptor localizations have lead
to many investigations on how the two subtypes are differentially involved in memory
tasks. For example, Ramos et al. (2005) demonstrated that endogenous activation of the
β1–AR impairs working memory in both rats and monkeys. In contrast, Ramos et al.
(2008) demonstrated that β2–AR activation in the pre-frontal cortex (PFC) can improve
spatial working memory in rats and monkeys. Consistent with this opposing effect of the
two receptor subtypes is the report of no effect on working memory when β1- and β2–
ARs were blocked with the non-selective β –AR antagonist propranolol. Neither
microinjection of propranolol into the PFC (Li & Mei, 1994), nor systemic administration
of propranolol (Arnsten & Goldman-Rakic, 1985) altered PFC function in monkeys.
The previously described studies show different effects of β1- and β2–ARs in
memory tasks, but those tasks are not particularly arousing for the animal subjects. In the
fear and drug literature, different roles of β1 or β2–AR activation have been reported.
For example, Flexner and colleagues (1985) reported that blocking β1-AR with betaxolol
suppressed inhibitory avoidance retrieval testing while blocking β2-AR with ICI 118,551
had no effect. Murchison and colleagues (2004) demonstrated similar effects within the
context-fear paradigm, as only β1-AR blockade with betaxolol (3 mg/kg) impaired
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memory retrieval. Additionally, they demonstrated that blocking β2–ARs with a low (1
mg/kg) or high (10 mg/kg) dose of ICI 118,551 does not block retrieval of a context fear
memory. They then targeted the hippocampus with bilateral infusions of propranolol,
nadolol, or betaxolol and found in all three conditions that the mice were unable to
retrieve the contextual fear memory. From this evidence, it appears that contextual
memory retrieval depends on activation of β1–ARs.This lab has data showing
hippocampal infusions of nadolol induces a persistent deficit in CPP retrieval (Otis,
Fitzgerald, & Mueller, in review), but the role of specific β –AR subtypes has not yet
been investigated.
Other studies using the CPP paradigm have examined the differential roles of β1or β2–AR activation. Bernardi et al. (2009) discovered that rats administered ICI 118,551
after a drug-free CPP test showed an attenuated preference during a subsequent test,
whereas betaxolol had no effect. Additionally, a post-test microinfusion of ICI 118,551
into the BLA also impaired subsequent expression of a CPP. Thus, β2 –ARs within the
amygdala are responsible for the reconsolidation of a cocaine CPP.
β –ARs are also involved in relapse, as demonstrated using the reinstatement
procedure. A priming injection of cocaine reinstates a CPP after the animal has gone
through extinction learning (Kelley, et. al, 2007; Mantsch, et. al, 2010; Mueller &
Stewart, 2000; Otis & Mueller, 2011; Rodriguez-Arias, et. al, 2009). Our lab has shown
that the retrieval deficit induced by propranolol abolishes cocaine-induced reinstatement
of a CPP (Otis & Mueller, 2011). Vranjkovic, Hang, Baker, & Mantsch (2012)
investigated β–AR subtypes in stress-induced reinstatement of an extinguished cocaine
CPP. Following place conditioning and extinction, they showed that exposure to a
stressor, such as forced swim, will reinstate the CPP. However, rats administered a high
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dose (20 mg/kg, i.p.), but not a lower dose (10 mg/kg, i.p.), of betaxolol prior to forced
swim do not show reinstatement of the CPP. Additionally, they found that both a 1
mg/kg, i.p. or a 2 mg/kg, i.p. dose of the β2-AR antagonist ICI 118,551 is also capable of
blocking stress-induced reinstatement of the previously extinguished CPP. Thus, both β1
and β2 –ARs may mediate retrieval under some conditions.
Overall, there is limited evidence suggesting that β1-AR activation is necessary
for memory retrieval whereas β2-AR activation is necessary for reconsolidation. This
dissociation, however, has not been explicitly or systematically tested. Another
possibility is that β–ARs in general are necessary for retrieval of a CPP. Thus, this study
focuses on examining the effects of different doses of specific β–AR subtype antagonists
on retrieval and reconsolidation of a cocaine CPP.
Overview
This thesis aims to determine if β1 –AR or β2 –AR blockers can block the initial
and/or subsequent retrieval of cocaine CPP when given systemically prior to the initial
CPP trial.
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Methods
Subjects
Eighty-four male Long-Evans rats weighing 250-275 grams were individually
housed in clear plastic cages. Rats were maintained on a 14 hour light/10 hour dark cycle
(lights on at 7am) and will have unlimited access to both water and standard laboratory
rat chow (Harlan Laboratories). Rats were weighed and handled daily. All experimental
protocols have been approved by the Institutional Animal Care and Use Committee at the
University of Wisconsin-Milwaukee in accordance with National Institutes of Health
guidelines.

Drugs and doses
For conditioning, cocaine HCl (National Institute on Drug Abuse) was dissolved
in sterile 0.9% saline at a concentration of 10 mg/mL, and administered i.p. at a dose of
10 mg/kg. To investigate the optimal dose for effective disruption of cocaine CPP
retrieval, we used both a high and low dose of both betaxolol and ICI 118,551. Betaxolol
is a selective β1-AR antagonist and ICI 118,551 is a selective β2-AR antagonist. Pilot
data shows that a low dose of 3 mg/kg (i.p.) of betaxolol is effective at attenuating a CPP
(see Figure 2), but this dose may not be sufficient to completely disrupt retrieval on
subsequent trials. Previous work by Bernardi et al. (2009) showed that betaxolol at 5 or
10 mg/kg i.p. had no effect when administered immediately after the first CPP trial (i.e.,
post-retrieval) on subsequent trials. However, post-retrieval administration does not
influence retrieval. Since Murchison and colleagues (2004) demonstrated blockade of
retrieval of contextual fear with a pre-trial injection of 3 mg/kg of betaxolol, this dose
was used as the low dose for attempting to block retrieval. Vranjkovic, Hang, Baker, and
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Mantsch (2012) showed that a high dose (20 mg/kg, i.p.) of betaxolol blocks stressinduced reinstatement. Thus, I also used this dose as my highest dose for attempting to
block retrieval.
Since ICI 118,551 has been shown to be effective at disrupting reconsolidation of
a cocaine CPP with a dose of 8 mg/kg (Bernardi et al., 2009), this will be the high dose of
ICI 118,551. This effective high dose will be cut in half to 4 mg/kg for the low dose to
investigate a dose response curve. Additionally, this lab has pilot data showing that
betaxolol, but not ICI 118,551, is effective at blocking retrieval (see Figure 2). To
determine the role of these β-AR subtypes in retrieval and reconsolidation, either a high
or low dose of betaxolol or ICI 118,551 will be injected i.p. 20 minutes before the initial
CPP trial.

Figure 2. Systemic administration of betaxolol 3 mg/kg, but not ICI 118,551 5 mg/kg or saline
prevented rats from expressing a CPP for the previously cocaine-paired chamber during the initial
CPP trial (n=8 per group). *p < 0.05
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Place preference apparatus
A three-chamber apparatus was used for testing and conditioning in which the two
larger chambers for conditioning (13” x 9” x 11.5”) are separated by a center chamber (6”
x 7” x 11.5”). One of the conditioning chambers has white walls and mesh wire flooring;
the other conditioning chamber has one black wall, three white walls, and a gold-grated
floor. The center chamber flooring is made of aluminum. Each chamber is raised 1.5” to
allow the use of removable trays for cleaning.
During conditioning, walls were placed between each chamber to isolate each rat
within a specific chamber. During baseline and CPP trials the walls were removed to
allow the rat access to all three chambers. Both of the larger chambers have two infrared
photobeams that are separated by 3”. The rat is determined to be in one of the larger
chambers if the beam furthest from the door is broken or in the center chamber if the
beam closest to the central chamber is broken. Throughout all phases of the experiment
the room lights were turned off and a single lamp was lit to keep the room in semidarkness.

Behavioral testing and injections
Baseline preferences were determined by placing the rats into the center chamber
with free access to the entire apparatus for 15 minutes. Time spent in each chamber were
recorded. In previous studies using the same 3-chamber apparatus, rats spent an
equivalent amount of time in the two larger conditioning chambers during baseline
testing. Therefore, I used an unbiased procedure, in which rats are randomly assigned to
receive cocaine in one of the two larger chambers independent of baseline preference
scores.
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Following baseline testing, rats were conditioned to associate one chamber, but
not another, with cocaine in a counterbalanced fashion over 8 days. Injections of saline
or cocaine were given immediately prior to each 20 minute conditioning session, during
which the rats will be confined to their respective chamber.
Following conditioning rats were subjected to daily CPP trials during which they
were placed into the center chamber and allowed free access to the entire apparatus for 15
minutes. A CPP will be determined when significantly more time is spent in the
previously cocaine-paired chamber than the saline-paired chamber. To test the effects of
β-AR subtype antagonists on retrieval, rats will be injected with one of the following 30
minutes prior to an initial CPP trial:
1.

3 mg/mg of betaxolol

2.

20 mg/kg of betaxolol

3.

4 mg/kg of ICI 118,551

4.

8 mg/kg of ICI 118,551

5.

1 ml/kg of saline (control)

Following the initial CPP trial, rats were given daily drug-free trials to determine if the
betaxolol or ICI 118,551 treatment induces a persistent effect.

Reinstatement
A priming injection of cocaine has been shown to reinstate a CPP after extinction
(Kelley, et. al, 2007; Mantsch, et. al, 2010; Mueller & Stewart, 2000; Otis & Mueller,
2011; Rodriguez-Arias, et. al, 2009). Previous work in the lab has demonstrated that a
propranolol-induced retrieval deficit persists, and importantly protects against cocaineinduced reinstatement (Otis & Mueller, 2011). Thus, I also investigated whether
blockade of β-AR subtypes during retrieval also provides protection against cocaine-
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induced reinstatement after extinction by injecting 5 mg/kg (i.p.) cocaine 15 minutes
prior to a final test.

Data analysis and statistics
Statistical analyses were performed using SPSS. Cocaine seeking was analyzed
by comparing time spent between the cocaine, saline, and center chambers across trials
and between groups using repeated measures ANOVA. If a significant effect of chamber
was found, post-hoc Tukey’s Honestly Significant Difference (HSD) tests will be used to
compare the amount of time spent in the cocaine-paired and saline-paired chambers
throughout the CPP trials.
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Results

Experiment 1A: Betaxolol attenuates retrieval of a CPP when administered prior to
an initial test
We first examined the necessity of β1-adrenergic receptor activation for the
retrieval of a cocaine-associated CPP. In experiment 1A, rats were pretested, conditioned
with 10 mg/kg of cocaine, and subjected to daily CPP trials. Thirty minutes prior to the
first CPP trial, rats were injected with either vehicle, a 3 mg/kg or 20 mg/kg dose of the
β1-adrenergic receptor antagonist betaxolol (n= 12 per group). The saline and 3 mg/kg
betaxolol group showed a CPP for the previously cocaine-paired chamber, while the 20
mg/kg betaxolol group did not (see Figure 3). Repeated measures ANOVA revealed a
significant effect of chamber for the saline (F2,22=30.20, p<0.05), 3 mg/kg betaxolol
(F2,22=24.87, p<0.05), and 20 mg/kg betaxolol groups (F2,22=7.41, p<0.05). Post hoc
analyses confirmed that the saline group spent significantly more time in the previously
cocaine-paired chamber than the saline-paired chamber (p<0.05) throughout all trials.
The 3 mg/kg betaxolol groups significantly more time in the previously cocaine-paired
chamber than the saline-paired (p<0.05) during the first trial. In contrast, the 20 mg/kg
betaxolol group spent a similar amount of time in the cocaine- and saline-paired
chambers (p>0.05) throughout all trials. Thus, a single 20 mg/kg dose, but not 3 mg/kg
treatment of betaxolol reduces expression of a CPP both initially and long after treatment.
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Figure 3. Systemic administration of betaxolol 20 mg/kg, but not 3 mg/kg or saline prevented rats from
expressing a CPP for the previously cocaine-paired chamber during the initial and subsequent CPP trials
(n=12 per group). *p < 0.05.

Next we determined whether the retrieval deficit induced by betaxolol would
prevent reinstatement of a CPP to a priming injection of cocaine. Rats continued to
receive additional drug-free CPP trials to ensure extinction of the CPP. Analysis of the
final extinction trial revealed a significant effect of chamber for the saline (F2,33=10.73,
p<0.05) and betaxolol 3 mg/kg groups (F2,33=10.10, p<0.05), but not for the betaxolol 20
mg/kg group (F2,33=.692, p>0.05; see Figure 4). Post hoc analyses showed that rats spent
a similar amount of time in the cocaine- and saline-paired chambers (p>.05), and less
time in the center chamber (p<.05). Two days later, rats were injected with cocaine (5
mg/kg, i.p.) 15 min before a CPP trial to test for reinstatement of the CPP. ANOVA
revealed a significant effect of chamber during the betaxolol-free cocaine-primed
reinstatement trial for the saline (F2,33=19.22, p<0.05) and 3 mg/kg betaxolol groups
(F2,33=13.97, p<0.05), but not for the 20 mg/kg betaxolol group (F2,33=1.25, p>0.05).
Post hoc analyses showed that saline and 3 mg/kg betaxolol-treated rats spent
significantly more time in the previously cocaine-paired chamber than saline-paired
chamber (p<0.01). Thus, a high dose, but not a low dose of betaxolol, is capable of
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disrupting retrieval of a CPP and preventing cocaine-induced reinstatement in the
absence of further betaxolol treatment.

Figure 4. Previous administration of betaxolol 20 mg/kg, but not 3 mg/kg and saline prevented rats from
expressing a CPP for the previously cocaine-paired chamber following a 5 mg/kg priming injection of
cocaine. (n=12 per group). *p < 0.05.

Experiment 1B: ICI 118,551 attenuates reconsolidation but not retrieval of a CPP
when administered prior to an initial test
We next examined the necessity of β2-adrenergic receptor activation for the
retrieval or reconsolidation of a cocaine-associated CPP. In experiment 1B, rats were
pretested, conditioned with 10 mg/kg of cocaine, and subjected to daily CPP trials.
Thirty min before the first CPP trial, they were administered either vehicle, a low 4
mg/kg, or high 8 mg/kg dose of the β2-adrenergic receptor antagonist ICI 118 (n= 12 per
group). The saline and 4 mg/kg ICI 118,551 group showed a CPP for the previously
cocaine-paired chamber throughout all trials, while the 8 mg/kg ICI 118,551 group
showed a CPP on trial 1, but not on subsequent trials (see Figure 5). Repeated measures
ANOVA revealed a significant effect of chamber for the saline (F2,22=30.20, p<0.05), 4
mg/kg ICI 118,551 group (F2,22=35.21, p<0.05), and 8 mg/kg ICI 118,551 group
(F2,22=24.68, p<0.05). Post hoc analyses confirmed that the saline group spent
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significantly more time in the previously cocaine-paired chamber than the saline-paired
(p<0.05) throughout all trials. Post hoc analyses confirmed both the 4 mg/kg ICI 118,551
(p<0.05) and 8 mg/kg ICI 118,551 (p<0.05)group spent significantly more time in the
previously cocaine-paired chamber than the saline chamber during the first trial.
However, during the second trial (p<0.05) and third trial (p<0.05) only the 4 mg/kg ICI
118,551 group spent significantly more time in the previously cocaine-paired chamber
than the saline chamber. Thus, a single 8 mg/kg but not 4 mg/kg treatment of ICI
118,551 can persistently attenuate reconsolidation of a CPP.

Figure 5. 4 mg/kg ICI 118,551 failed to attenuate CPP expression during the initial trial or on subsequent
drug-free trials. 8 mg/kg ICI 118,551 failed to attenuate CPP expression during the initial test trial, but lead
to attenuation of a CPP on subsequent trials (n = 12 per group). * p < 0.05, *** p < 0.001

Next we determined whether the reconsolidation deficit induced by ICI 118,551
would prevent reinstatement of a CPP to a priming injection of cocaine. Rats continued to
receive additional drug-free CPP trials to ensure extinction of the CPP. ANOVA on the
final extinction trial revealed a significant effect of chamber for the saline group
(F2,33=10.73, p<0.05), ICI 118,551 4 mg/kg group (F2,33=4.78, p<0.05), and ICI 118,551
8 mg/kg group (F2,33=7.43, p<0.05). Post hoc analyses showed that during the final
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extinction trial a similar amount of time was spent in the cocaine- and saline-paired
chamber (p>.05), although a significantly greater amount of time was spent in the cocaine
chamber than the center chamber for all groups (p<.05; see Figure 6). Two days later, rats
were injected with cocaine (5 mg/kg, i.p.) 15 min before a CPP trial to test for
reinstatement of the CPP. ANOVA revealed a significant effect of chamber during the
ICI 118,551-free cocaine-primed reinstatement trial for the saline (F2,33=19.22, p<0.05)
and 8 mg/kg ICI groups (F2,33=5.962, p<0.05), but not in the 4 mg/kg ICI group
(F2,33=2.43, p>0.05). Post hoc analyses revealed that the saline group spent more time in
the cocaine- than saline-paired chamber (p<.05), but neither ICI-treated group showed a
CPP. Thus, ICI 118,551 at either a low or high dose prevents cocaine-induced
reinstatement in the absence of further ICI 118,551 treatment.

Figure 6. Previous administration of saline failed to prevent rats from expressing a CPP whereas 4 or 8
mg/kg of ICI 118,551 prevented rats from expressing a CPP for the previously cocaine-paired chamber
following a 5 mg/kg priming injection of cocaine (n=12 per group). *p < 0.05.
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Experiment 2: Co-administration of betaxolol and ICI 118,551 persistently disrupts
retrieval of CPP when administered prior to an initial test

Next, we investigated the effect of co-injections of both high doses of betaxolol
and ICI 118,551 on retrieval of a CPP. In experiment 2 rats were pretested, conditioned
with 10 mg/kg of cocaine, and subjected to daily CPP trials. Thirty min before the first
CPP trial, rats were injected with either vehicle or a 20 mg/kg dose of betaxolol
combined with a 8 mg/kg dose of ICI 118,551 (n= 12 per group). The saline group
showed a CPP for the previously cocaine-paired chamber throughout trials whereas the
co-injected group showed a retrieval deficit (see Figure 7). Repeated measures ANOVA
revealed a significant effect of chamber for both the saline (F2,22=24.87, p<0.05) and the
co-injected groups (F2,22=5.42, p<0.05). Post hoc analyses confirmed for the saline
group that significantly more time was spent in the previously cocaine-paired chamber
than the saline-paired chamber on all trials (p<0.01). For the co-injected group, post hoc
analyses showed that rats spent similar time in the cocaine- and saline-paired chambers
(p>.05), although less time was spent in the center chamber (p<0.05). Thus, a single coinjection of 20 mg/kg betaxolol and 8 mg/kg of ICI 118,551 can persistently disrupt
retrieval of a CPP throughout multiple trials, replicating previously reported results using
a non-specific antagonist propranolol (Otis and Mueller, 2011).
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Figure 7. Co-injection of β1- and β2-receptor antagonist injected prior to first trial induces a persistent
retrieval deficit for a cocaine CPP (n = 12 per group). *** p < 0.001

Next we determined if co-injection of betaxolol and ICI 118,551 on the first CPP
trial would prevent subsequent reinstatement of a CPP to a priming injection of cocaine.
Rats continued to receive additional drug-free CPP trials to ensure extinction of the CPP.
Analysis of the rats final extinction trial via ANOVA revealed a significant effect of
chamber for the saline (F2,33=14.69, p<0.05) and co-injected group (F2,33=18.46, p<0.05).
Post hoc analyses confirmed that during the final extinction trial a similar amount of time
was spent in the saline- and cocaine-paired chambers (p>.05), although rats spent less
time in the center chamber (p<.05; see Figure 8). Two days later, rats were injected with
cocaine (5 mg/kg, i.p.) 15 min before a CPP trial to test for reinstatement of the CPP.
ANOVA revealed a significant effect of chamber during the betaxolol-ICI 118,551-free
cocaine-primed reinstatement trial for the saline (F2,33=15.92, p<0.05) and co-injected
groups (F2,33=10.42, p<0.05). Post hoc analyses revealed that saline-treated rats spent
significantly more time in the previously cocaine-paired than the saline-paired chamber
(p<0.01), whereas no differences were observed in the co-injected group. Thus, co-
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injection of betaxolol and ICI 118,551 prior to the first CPP trial prevented subsequent
cocaine-induced reinstatement in the absence of further treatment.

Figure 8. Co-injection of β1- and β2-receptor antagonist injected prior to first trial prevent reinstatement of
a CPP following a 5 mg/kg priming injection of cocaine * p < 0.05

Effects of drugs on locomotion activity
To determine whether the effects of betaxolol or ICI were due to alterations in
motor behavior, locomotion responses to betaxolol, ICI 118,551, and co-injections of
betaxolol plus ICI 118,551 were examined (Figure 9). None of the single injections of
betaxolol or ICI 118,551 had any significant effect on locomotion (ANOVA; F1,22=9.62,
p>0.05 for betaxolol; F1,22=14.17, p>0.05 for ICI 118,551). When betaxolol and ICI
118,551 were co-injected, locomotion activity significantly decreased in comparison to
controls (p< .05). Thus, the combination of the two drugs may have altered overall motor
behavior. This decrease in locomotion is similar to previous reports of 20 mg/kg
propranolol to also have a decreasing effect on locomotion (Mantsch et al., 2009).
However, this locomotion effect was not observed past the first trial so is not believed to
have any enduring effect on the animals behavior..
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Figure 9. Effects of locomotion activity from single injection or co-injection of betaxolol, ICI 118,551 on
either pre-test, first test trial (Ext 1), last extinction trial and after receiving 5 mg/kg priming injection of
cocaine. The only significant change observed was a decrease in the number of photobeam breaks for the
co-injection group in comparison to their control group on Ext 1. * p < 0.05
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Discussion
General Discussion
The present study investigated the roles of β1 and β2 adrenergic receptor subtypes
in the retrieval and reconsolidation of a cocaine conditioned place preference. Consistent
with our predictions, we found that β1-AR blockade led to impaired retrieval whereas β2AR blockade led to impaired reconsolidation of a cocaine CPP. At the highest dose, the
β1-AR antagonist betaxolol induced a persistent retrieval deficit. Furthermore, rats
treated with the highest dose of betaxolol did not show subsequent cocaine-induced
reinstatement. In contrast, the β2-AR antagonist ICI 118,551 did not affect retrieval but
rather disrupted reconsolidation of a cocaine CPP. The lowest dose of ICI 118,551 had
no effect, but the highest dose disrupted drug seeking on trials two and three.
Additionally, ICI 118,551 treatment overall prevented subsequent reinstatement to a
priming injection of cocaine, with the high dose having a greater effect than the low dose.
Finally, co-injection of betaxolol and ICI 118,551 induced a persistent retrieval deficit
and prevented subsequent reinstatement to a priming injection of cocaine in a similar
manner as the general β-AR antagonist propranolol (Otis and Mueller, 2011).
Previous work has shown that structures such as the PL-mPFC (Otis, et al., 2013)
or hippocampus (Otis, Fitzgerald, & Mueller, in review) play a role in retrieval but not
reconsolidation of a CPP. In both the PL-mPFC and hippocampus β1-ARs account for
over 80% of the total β-ARs (Rainbow, Parsons, & Wolfe, 1984). Thus, β1-ARs in these
regions may mediate retrieval, although this remains to be determined. The present
findings are consistent with previous work showing that both betaxolol and propranolol
produce similar retrieval deficits in contextual fear learning (Murchinson et al., 2004;
Flexner et al., 1985). Betaxolol was effective when given prior to the first trial, which
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may explain why other groups did not observe any deficits following post-trial injections
at various doses (Bernardi et al., 2009). We conclude that β1-ARs are critical for
retrieval but not reconsolidation of a cocaine CPP.
Our findings that β2-ARs mediate reconsolidation of a cocaine CPP is consistent
with previous findings from our lab and others (Bernardi et al., 2009). Additionally,
previous work has shown that the amygdala is involved with reconsolidation but not
retrieval of a CPP (Otis et al., 2013). Interestingly, β-AR distribution varies across
different nuclei of the amygdala. The BLA in the rat brain has been reported to express
65% β1-ARs, 35% β2-ARs; the lateral central nucleus expresses 60% β1-ARs, 40% β2ARs; and the medial central nucleus expresses roughly 53% β1-ARs, 47% β2-ARs
(Rainbow, Parsons, Wolfe, 1984). Drug experience may alter this distribution as
expression of β1-AR, but not β2-AR, significantly increased during withdrawal from
cocaine in rats (Rudoy and Van Bockstael, 2007). In these rats, administration of 5
mg/kg,i.p. of betaxolol resulted in a significant attenuation of anxiety-like behavior which
is characteristic during cocaine withdrawal (Rudoy and Van Bockstael, 2007). Since the
amygdala mediates anxiety (Davis, 1992; Bremner et al., 1996; Tanaka et al.,
2000; Charney, 2003) and is potently activated during withdrawal from various drugs of
abuse, including cocaine (Zhou et al., 2003; Pollandt et al., 2006), it is possible that β1AR may mediate symptoms of withdrawal. Thus, β-ARs in the amygdala mediate
reconsolidation through actions at β2-ARs and may participate in withdrawal in a β1-AR
dependent fashion.
Although our findings implicate that retrieval of a CPP is mediated by β1-ARs,
one possibility for the initial attenuation of the CPP is that betaxolol may induce an
aversive or appetitive state. No work has been done yet to confirm if betaxolol induces a
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CPP or aversion, however in Rudoy and Van Bockstael’s (2007) experiments, betaxolol
did not produce anxiolytic-like effects in control animals. We do not believe betaxolol
would create a preference or aversion because the retrieval deficit was observed on
subsequent betaxolol-free trials. Furthermore, conditioning with the general β-AR
antagonist propranolol does not induce a preference or aversion on a subsequent test trial
(Otis and Mueller, 2011). Regarding the β2-AR antagonist ICI 118,551, Bernardi et al.,
(2009) demonstrated that administration of ICI 118,551 following a single CS exposure
had no effect on a subsequent test. This suggests that ICI 118,551 at the high dose we
used was not by itself aversive. Since neither propranolol nor ICI 118,551 created a
preference or aversion, we do not believe betaxolol would cause a preference or aversion
effect, but a follow-up study is needed.
Another possible explanation of our results is that betaxolol or ICI 118,551
facilitated the extinction of a CPP. It is well accepted that norepinephrine facilitates,
rather than impedes, memory formation through β -receptor activation (McGaugh, 2000).
Previous work with non-selective beta blockers has demonstrated that propranolol
impairs extinction learning (Mueller and Cahill, 2010) in aversive (Merlo and Izquierdo,
1967; Mueller et al., 2008; Ouyang and Thomas, 2005) and appetitive paradigms
(LaLumiere et al., 2010).

Potential Mechanism
Activation of β-ARs in the CNS activates adenylyl cyclase to increase the levels
of intracellular cAMP, which activates protein kinase A (PKA) (Mueller, Porter, &
Quirk, 2008). PKA in turn phosphorylates calcium activated potassium channels and
blocks their activity. Accordingly, norepinephrine can increase the firing of a neuron by
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removing the hyperpolarizing currents that inhibit it activity (Madison and Nicoll, 1986).
Interestingly, equal doses of the non-selective β–AR agonist, isoproterenol, stimulates
β2-AR adenlyl cyclase approximately 50% more than β1-AR even though both β–AR
subtypes show equal affinity for isoproterenol (Green, Holt, & Liggett, 1992). Both β–
AR subtypes are distributed across dendrites (Joels and Baram, 2009) and stimulate
adenylyl cyclase by coupling to the guanine nucleotide protein which leads to the
increase of intracelluar cAMP and activation of PKA. Past work has shown that β adrenergic signaling is necessary for CPP retrieval (Jasmin et al, 2006; Olson et al, 2006).
Activity within the locus coeruleus, a cell body region for noradrenergic neurons, has
been shown to have a graded response to stimuli, responding greatest to salient stimuli
and subsequently leading to better retrieval (Sara, 2009). For example, human studies
have shown that propranolol administration can attenuate cued recall of heroin- or
emotionally-related words (Kroes, Strange, & Dolan, 2010; Zhao et al., 2010). Using the
CPP procedure, cocaine administration is paired with a distinguishable cue of a specific
conditioning chamber. Previous work has shown to block memory retrieval or
reconsolidation via norepinephrine blockade at β-ARs within structures mediating
retrieval or reconsolidation of a cocaine CPP, the β-AR antagonist must be active in the
presence of the drug-associated cues for the specific drug associations to be disrupted
(Otis et al., 2013; Bernardi et al., 2009). Thus disrupting noradrenergic signaling in the
presence of the previously associated drug cues prevents drug-seeking.
Clinical Relevance
Since our work and others (Vranjkovic et al., 2012) has shown that β2-AR
blockade is capable of blocking stress- or cocaine-induced reinstatement, ICI 118,551
could serve as a potential in or out-patient medication for both men and women that may
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have to return to stressful or environmental cues during or after treatment. A recent fMRI
study shows that in cocaine dependence, corticostriatal-limbic hyperactivity appears to be
linked to stress cues in women and drug cues in men (Potenza et al., 2012). Although
men are more likely to have a cocaine abuse or dependence disorder (Brady and Randall,
1999), women begin using cocaine at an earlier age (Chen and Kandel, 2002) and
progress more rapidly from casual use to a dependence disorder (O'Brien and Anthony
2005). Differences also exist between men and women in terms of relapse to cocaine
use. For example, women tend to have shorter cocaine-free periods (Kosten et al., 1996),
with some reports indicating an enhanced likelihood to relapse (Hyman et al., 2008)
following exposure to stressful stimuli/life events or depression, factors that have been
implicated as the leading cause of relapse in people (Sinha, 2009). Taken together, those
who are dealing with either stress or drug cues as a cause to use could potentially benefit
from β2-AR blockade.
In summary, these findings further suggest that central noradrenergic systems
contribute to the retrieval and reconsolidation of drug-associated memories. Because
presentation of drug-associated stimuli promotes drug seeking and relapse in addicts who
have even gone through exposure therapy, using betaxolol, ICI 118,551 or a combination
of the two in adjunct with exposure therapy could help limit the relapse vulnerability of
addicts by disrupting stimulus-induced drug seeking even after treatment has ended.

Future Directions
Future work will focus on the following aspects: the success of ICI 118,551
following both longer cocaine exposure and after multiple cocaine or stress relapses,
replication of these experiments but involving female rats, microinfusions of betaxolol or
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ICI 118,551 in the PL-mPFC or hippocampus, and electrophysiology using betaxolol or
ICI 118,551. The current study shows the success after one priming injection, but the
continuous relapse rates prevalent in people suggests an investigation is needed of the
potential success of ICI 118,551 for cocaine addicts of extended use in addition to several
cue or stress induced relapses. Also, the current study demonstrates the success of
betaxolol or ICI 118,551 with male rats. As mentioned before there are several
differences in cocaine addiction between men and women. It remains unknown if ICI
118,551 protecting effect against stress or cocaine induced reinstatement translates over
from males to females.
As described before there are differences in distributions of β1-AR and β2-AR
throughout the brain. An investigation of microinfusions of either betaxolol or ICI
118,551 into the PL-mPFC or hippocampus could open a potential discussion of specific
structures in the brain that mediate retrieval rather than subtypes. At the current moment
we would hypothesize that infusions of betaxolol would create similar results of nadolol
(Otis et al., 2013), but it remains uncertain if ICI 118,551 could disrupt retrieval. In
addition to the said microinfusion studies, electrophysiology studies could reveal what
concentrations of betaxolol, ICI 118,551 or betaxolol and ICI 118,551 would be needed
to replicate the effects of propranolol nullifying the increased excitability of
norepinephrine on a neuron (Otis et al., 2013).
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